Perspective Therapeutics (CATX) Cash from Financing Activities (2010 - 2026)

Perspective Therapeutics (CATX) has 16 years of Cash from Financing Activities data on file, last reported at $164.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 1548.09% year-over-year to $164.4 million; the trailing twelve-month figure through Mar 2026 stood at $164.7 million (up 23.8% YoY), and the FY2025 full-year result was $10.3 million, down 96.44% from the prior year.
• Cash from Financing Activities improved to $164.4 million in Q1 2026, from -$13000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $166.3 million in Q1 2024 to a low of -$80000.0 in Q1 2023.
• A 5-year average of $31.0 million and a median of $345000.0 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 208010.0% in 2024 and tumbled 103.77% in 2025, its largest moves.
• Tracing CATX's Cash from Financing Activities over 5 years: stood at $28000.0 in 2022, then surged by 1157.14% to $352000.0 in 2023, then fell by 1.99% to $345000.0 in 2024, then plunged by 103.77% to -$13000.0 in 2025, then surged by 1264438.46% to $164.4 million in 2026.
• Business Quant data shows CATX's Cash from Financing Activities at $164.4 million in Q1 2026, -$13000.0 in Q4 2025, and $213000.0 in Q3 2025.